Clinical roundtable monograph. Current treatment options for metastatic breast cancer

what now?

Hope S. Rugo, Joyce A. O'Shaughnessy, Edith A. Perez

Research output: Contribution to journalArticle

Abstract

Approximately 30% of patients with breast cancer will develop metastatic breast disease. Metastatic breast cancer is considered an incurable disease, with complete remission rarely achieved after treatment. The goal of treatment for metastatic breast cancer patients is to increase overall survival time and delay disease progression while ameliorating symptoms and improving or maintaining quality of life. Single-agent therapeutic regimens are appropriate for most metastatic breast cancer patients. Patients with the luminal A subtype of breast cancer, which is more indolent in nature and tends to be more sensitive to treatment in general, often respond well to single-agent therapy. Several chemotherapy regimens are recommended for the treatment of metastatic breast cancer. Compared with single-agent regimens, these combination regimens often produce a greater improvement in the rate of objective response as well as a prolongation of progression-free survival. There is little evidence, however, of improvement in overall survival. Combination chemotherapy regimens are often associated with a greater degree of toxicity depending on schedules and doses used. The use of bevacizumab in metastatic breast cancer is currently a topic of controversy. It is hoped that forthcoming trial data will enable the identification of a group of patients, based on tumor biology, who could benefit from bevacizumab-based therapy.

Original languageEnglish (US)
Pages (from-to)1-16
Number of pages16
JournalClinical advances in hematology & oncology : H&O
Volume9
Issue number11
StatePublished - Nov 2011
Externally publishedYes

Fingerprint

Breast Neoplasms
Therapeutics
Social Identification
Breast Diseases
Survival
Combination Drug Therapy
Disease-Free Survival
Disease Progression
Appointments and Schedules
Quality of Life
Drug Therapy
Neoplasms
Bevacizumab

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Clinical roundtable monograph. Current treatment options for metastatic breast cancer : what now? / Rugo, Hope S.; O'Shaughnessy, Joyce A.; Perez, Edith A.

In: Clinical advances in hematology & oncology : H&O, Vol. 9, No. 11, 11.2011, p. 1-16.

Research output: Contribution to journalArticle

Rugo, Hope S. ; O'Shaughnessy, Joyce A. ; Perez, Edith A. / Clinical roundtable monograph. Current treatment options for metastatic breast cancer : what now?. In: Clinical advances in hematology & oncology : H&O. 2011 ; Vol. 9, No. 11. pp. 1-16.
@article{c53ba9f5cd0343a59e9ed1b3de415406,
title = "Clinical roundtable monograph. Current treatment options for metastatic breast cancer: what now?",
abstract = "Approximately 30{\%} of patients with breast cancer will develop metastatic breast disease. Metastatic breast cancer is considered an incurable disease, with complete remission rarely achieved after treatment. The goal of treatment for metastatic breast cancer patients is to increase overall survival time and delay disease progression while ameliorating symptoms and improving or maintaining quality of life. Single-agent therapeutic regimens are appropriate for most metastatic breast cancer patients. Patients with the luminal A subtype of breast cancer, which is more indolent in nature and tends to be more sensitive to treatment in general, often respond well to single-agent therapy. Several chemotherapy regimens are recommended for the treatment of metastatic breast cancer. Compared with single-agent regimens, these combination regimens often produce a greater improvement in the rate of objective response as well as a prolongation of progression-free survival. There is little evidence, however, of improvement in overall survival. Combination chemotherapy regimens are often associated with a greater degree of toxicity depending on schedules and doses used. The use of bevacizumab in metastatic breast cancer is currently a topic of controversy. It is hoped that forthcoming trial data will enable the identification of a group of patients, based on tumor biology, who could benefit from bevacizumab-based therapy.",
author = "Rugo, {Hope S.} and O'Shaughnessy, {Joyce A.} and Perez, {Edith A.}",
year = "2011",
month = "11",
language = "English (US)",
volume = "9",
pages = "1--16",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "11",

}

TY - JOUR

T1 - Clinical roundtable monograph. Current treatment options for metastatic breast cancer

T2 - what now?

AU - Rugo, Hope S.

AU - O'Shaughnessy, Joyce A.

AU - Perez, Edith A.

PY - 2011/11

Y1 - 2011/11

N2 - Approximately 30% of patients with breast cancer will develop metastatic breast disease. Metastatic breast cancer is considered an incurable disease, with complete remission rarely achieved after treatment. The goal of treatment for metastatic breast cancer patients is to increase overall survival time and delay disease progression while ameliorating symptoms and improving or maintaining quality of life. Single-agent therapeutic regimens are appropriate for most metastatic breast cancer patients. Patients with the luminal A subtype of breast cancer, which is more indolent in nature and tends to be more sensitive to treatment in general, often respond well to single-agent therapy. Several chemotherapy regimens are recommended for the treatment of metastatic breast cancer. Compared with single-agent regimens, these combination regimens often produce a greater improvement in the rate of objective response as well as a prolongation of progression-free survival. There is little evidence, however, of improvement in overall survival. Combination chemotherapy regimens are often associated with a greater degree of toxicity depending on schedules and doses used. The use of bevacizumab in metastatic breast cancer is currently a topic of controversy. It is hoped that forthcoming trial data will enable the identification of a group of patients, based on tumor biology, who could benefit from bevacizumab-based therapy.

AB - Approximately 30% of patients with breast cancer will develop metastatic breast disease. Metastatic breast cancer is considered an incurable disease, with complete remission rarely achieved after treatment. The goal of treatment for metastatic breast cancer patients is to increase overall survival time and delay disease progression while ameliorating symptoms and improving or maintaining quality of life. Single-agent therapeutic regimens are appropriate for most metastatic breast cancer patients. Patients with the luminal A subtype of breast cancer, which is more indolent in nature and tends to be more sensitive to treatment in general, often respond well to single-agent therapy. Several chemotherapy regimens are recommended for the treatment of metastatic breast cancer. Compared with single-agent regimens, these combination regimens often produce a greater improvement in the rate of objective response as well as a prolongation of progression-free survival. There is little evidence, however, of improvement in overall survival. Combination chemotherapy regimens are often associated with a greater degree of toxicity depending on schedules and doses used. The use of bevacizumab in metastatic breast cancer is currently a topic of controversy. It is hoped that forthcoming trial data will enable the identification of a group of patients, based on tumor biology, who could benefit from bevacizumab-based therapy.

UR - http://www.scopus.com/inward/record.url?scp=84879456732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879456732&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 1

EP - 16

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 11

ER -